Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$32.43 -0.9%	$34.40	$29.31 ▼ $61.38	$3.87B	0.59	1.54 million shs	2.41 million shs
ELVN Enliven Therapeutics	$21.30 -1.3%	$18.88	$13.30 ▼ $30.03	$1.05B	0.79	291,067 shs	518,501 shs
KRYS Krystal Biotech	$132.46 +0.3%	$143.35	$122.80 ▼ $219.34	$3.83B	0.65	286,027 shs	691,210 shs
SRPT Sarepta Therapeutics	$20.08 -3.3%	$43.10	$18.30 ▼ $168.31	$1.97B	0.61	2.05 million shs	12.63 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	0.00%	-5.67%	+6.36%	-28.62%	-37.56%
ELVN Enliven Therapeutics	0.00%	-2.78%	+27.01%	+1.04%	+4.05%
KRYS Krystal Biotech	0.00%	-3.36%	+5.72%	-29.22%	-23.43%
SRPT Sarepta Therapeutics	0.00%	-44.50%	-48.23%	-72.90%	-82.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYTK Cytokinetics	4.2029 of 5 stars	4.5	3.0	4.6	1.5	0.8	0.0
ELVN Enliven Therapeutics	2.6519 of 5 stars	3.5	1.0	0.0	3.1	4.2	0.0
KRYS Krystal Biotech	4.4576 of 5 stars	3.5	1.0	4.7	2.7	2.5	1.9
SRPT Sarepta Therapeutics	4.5331 of 5 stars	4.2	2.0	4.2	1.5	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTK Cytokinetics	2.93	Moderate Buy	$70.92	118.70% Upside
ELVN Enliven Therapeutics	3.00	Buy	$39.60	85.92% Upside
KRYS Krystal Biotech	3.00	Buy	$211.13	59.39% Upside
SRPT Sarepta Therapeutics	2.46	Hold	$67.64	236.85% Upside

Current Analyst Ratings Breakdown

Latest ELVN, CYTK, SRPT, and KRYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	SRPT Sarepta Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$123.00 ➝ $45.00
6/20/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
6/18/2025	SRPT Sarepta Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$85.00 ➝ $40.00
6/18/2025	SRPT Sarepta Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00
6/17/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$50.00 ➝ $25.00
6/17/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$29.00
6/17/2025	SRPT Sarepta Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $30.00
6/17/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$100.00 ➝ $75.00
6/17/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$89.00 ➝ $29.00
6/17/2025	SRPT Sarepta Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTK Cytokinetics	$18.47M	209.70	N/A	N/A	($1.15) per share	-28.20
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
KRYS Krystal Biotech	$290.52M	13.18	$4.64 per share	28.56	$32.90 per share	4.03
SRPT Sarepta Therapeutics	$1.90B	1.04	$2.44 per share	8.24	$15.99 per share	1.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTK Cytokinetics	-$589.53M	-$5.29	N/A	N/A	N/A	-3,201.47%	N/A	-43.75%	8/6/2025 (Estimated)
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.16	31.84	13.14	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	1.84	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)

Latest ELVN, CYTK, SRPT, and KRYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/6/2025	Q1 2025	CYTK Cytokinetics	-$1.41	-$1.36	+$0.05	-$1.36	$2.77 million	$1.60 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTK Cytokinetics	N/A	5.99	5.99
ELVN Enliven Therapeutics	N/A	21.07	21.06
KRYS Krystal Biotech	N/A	9.65	9.27
SRPT Sarepta Therapeutics	1.00	4.02	2.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTK Cytokinetics	N/A
ELVN Enliven Therapeutics	95.08%
KRYS Krystal Biotech	86.29%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
CYTK Cytokinetics	2.70%
ELVN Enliven Therapeutics	25.90%
KRYS Krystal Biotech	13.70%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTK Cytokinetics	250	119.43 million	116.20 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable

ELVN, CYTK, SRPT, and KRYS Headlines

Recent News About These Companies

Sarepta Therapeutics (NASDAQ:SRPT) Earns "Market Perform" Rating from William Blair

June 22 at 1:13 AM | americanbankingnews.com

Sarepta Therapeutics (SRPT) Faces Setback Amid Gene Therapy Concerns

June 21 at 5:49 PM | gurufocus.com

Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $45.00 at Oppenheimer

June 21 at 1:57 AM | americanbankingnews.com

William Blair Downgrades Sarepta Therapeutics (SRPT)

June 20 at 3:27 PM | msn.com

Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand

June 20 at 2:10 PM | benzinga.com

Sarepta Therapeutics (NASDAQ:SRPT) Given New $45.00 Price Target at Oppenheimer

June 20 at 11:08 AM | marketbeat.com

This Sarepta Therapeutics Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday

June 20 at 11:05 AM | benzinga.com

SRPT INQUIRY: Sarepta Therapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law (NASDAQ:SRPT)

June 20 at 9:08 AM | globenewswire.com

Sarepta Therapeutics (NASDAQ:SRPT) Given "Market Perform" Rating at William Blair

June 20 at 8:29 AM | marketbeat.com

TD Cowen Downgrades Sarepta Therapeutics (NASDAQ:SRPT) to Hold

June 20 at 2:29 AM | americanbankingnews.com

What’s next for Sarepta Therapeutics with gene therapy under fire?

June 19 at 11:10 AM | statnews.com

Deutsche Bank Aktiengesellschaft Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

June 19 at 4:03 AM | americanbankingnews.com

Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to Hold at The Goldman Sachs Group

June 19 at 4:03 AM | americanbankingnews.com

Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $75.00 at Wells Fargo & Company

June 19 at 1:43 AM | americanbankingnews.com

Sarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT)

June 19 at 1:11 AM | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

June 18, 2025 | globenewswire.com

Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences (SRPT)

June 18, 2025 | marketbeat.com

Mizuho Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $40.00

June 18, 2025 | marketbeat.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 3% After Analyst Downgrade

June 18, 2025 | marketbeat.com

Sarepta Stock (SRPT) Could Soar 200% Despite Growing Caution on Wall Street

June 18, 2025 | tipranks.com

SRPT NOTICE: Did Sarepta Therapeutics, Inc. Mislead Investors about the Safety of Elevidys? Contact BFA Law if You Lost Money (NASDAQ:SRPT)

June 18, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN, CYTK, SRPT, and KRYS Company Descriptions

Cytokinetics NASDAQ:CYTK

$32.43 -0.30 (-0.92%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$32.28 -0.15 (-0.46%)

As of 06/20/2025 07:27 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Enliven Therapeutics NASDAQ:ELVN

$21.30 -0.27 (-1.25%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$21.30 0.00 (0.00%)

As of 06/20/2025 04:53 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Krystal Biotech NASDAQ:KRYS

$132.46 +0.37 (+0.28%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$132.52 +0.06 (+0.05%)

As of 06/20/2025 06:07 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Sarepta Therapeutics NASDAQ:SRPT

$20.08 -0.69 (-3.32%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$20.10 +0.02 (+0.10%)

As of 06/20/2025 07:59 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time